Allogene Therapeutics, Inc., a clinical-stage biotechnology company (Nasdaq: ALLO) based in South San Francisco, has scheduled its release of the first quarter financial results for 2026 along with a business update on May 13, 2026. The announcement is set to occur after the market closes, followed by a live audio webcast and conference call at 2 p.m. PT/5 p.m. ET. Allogene focuses on developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease.